ABT1

Across TCGA pan-cancer cohorts, ABT1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ABT1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ABT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

KIRP, LIHC, and LUSC are the cancer types where ABT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	36	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
LUSC	OS	Median	All	0.511	0.762	<.001	8	view →
SARC	OS	Median	All	0.108	0.827	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.626	.044	2	view →
SKCM	DFS	Median	II,III,IV	0.741	0.218	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ABT1–KIRP (OS)

Open the KIRP breakdown →